Related Experiment Video
Updated: Nov 10, 2025
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
Isoform-Selective NFAT Inhibitor: Potential Usefulness and Development
Noriko Kitamura1, Osamu Kaminuma1,2
1Laboratory of Allergy and Immunology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Abstract:
Nuclear factor of activated T cells (NFAT), which is the pharmacological target of immunosuppressants cyclosporine and tacrolimus, has been shown to play an important role not only in T cells (immune system), from which their name is derived, but also in many biological events. Therefore, functional and/or structural abnormalities of NFAT are linked to the pathogenesis of diseases in various organs. The NFAT protein family consists of five isoforms, and each isoform performs diverse functions and has unique expression patterns in the target tissues. This diversity has made it difficult to obtain ideal pharmacological output for immunosuppressants that inhibit the activity of almost all NFAT family members, causing serious and wide-ranging side effects. Moreover, it remains unclear whether isoform-selective NFAT regulation can be achieved by targeting the structural differences among NFAT isoforms and whether this strategy can lead to the development of better drugs than the existing ones. This review summarizes the role of the NFAT family members in biological events, including the development of various diseases, as well as the usefulness of and problems associated with NFAT-targeting therapies, including those dependent on current immunosuppressants. Finally, we propose a novel therapeutic strategy based on the molecular mechanisms that enable selective regulation of specific NFAT isoforms.
Insights
Nuclear factor of activated T cells (NFAT) are crucial in immunity and disease. Targeting specific NFAT isoforms offers a novel therapeutic strategy to improve drug efficacy and reduce side effects associated with current broad-spectrum immunosuppressants.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Nuclear factor of activated T cells (NFAT) are key regulators in T cells and other biological processes.
- Dysfunctional NFAT is implicated in the pathogenesis of various organ-specific diseases.
- The NFAT family comprises five isoforms with distinct functions and expression patterns.
Purpose of the Study:
- To review the roles of NFAT family members in biological events and disease development.
- To analyze the efficacy and limitations of current NFAT-targeting therapies, including immunosuppressants like cyclosporine and tacrolimus.
- To explore the potential of isoform-selective NFAT regulation for developing improved therapeutics.
Main Methods:
- Literature review of NFAT functions, disease associations, and therapeutic strategies.
- Analysis of structural differences among NFAT isoforms.
- Evaluation of current immunosuppressants targeting NFAT activity.
Main Results:
- NFAT proteins are involved in diverse biological functions and disease pathogenesis.
- Current broad-acting immunosuppressants targeting NFAT cause significant side effects due to inhibiting multiple isoforms.
- Isoform-selective targeting of NFAT remains largely unexplored but holds therapeutic promise.
Conclusions:
- Targeting specific NFAT isoforms could overcome the limitations of current broad-spectrum immunosuppressants.
- Developing drugs that selectively regulate NFAT isoforms may lead to more effective and safer therapies.
- Further research into molecular mechanisms for isoform-selective NFAT regulation is warranted.
